In this episode, we discuss a phase II study by Chen Li and colleagues that evaluates the efficacy and safety of toripalimab, a PD-1 inhibitor, combined with bevacizumab and platinum-based chemotherapy as a first-line treatment for refractory recurrent or metastatic cervical cancer. With an impressive objective response rate of 83.3% and a median progression-free survival of 22.6 months, the findings highlight a promising alternative for patients with limited options. The discussion also explores the regimen’s manageable safety profile and its potential to optimize dosing strategies. Tune in for insights into this innovative approach that could reshape the treatment landscape for advanced cervical cancer.

Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214) (https://doi.org/10.3802/jgo.2025.36.e44)